Atorvastatin Calcium 80 mg tablets recalled for manufacturing quality deviations
Accord Healthcare recalls Atorvastatin Calcium 80 mg tablets due to manufacturing process deviations identified during FDA inspection. 72,376 bottles were distributed in the US, Puerto Rico, and Canada.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for manufacturing quality deviations without any reported illnesses or injuries. The recall represents a risk-of-harm situation due to manufacturing process failures, but the absence of reported adverse events places this at the High level rather than Severe.
Plain-English summary
Accord Healthcare, Inc. is recalling Atorvastatin Calcium Tablets USP 80 mg due to Current Good Manufacturing Practice (CGMP) deviations identified during an FDA inspection. The recalled product includes tablets packaged as 90-tablet bottles (NDC 16729-047-15) and 500-tablet bottles (NDC 16729-047-16).
Current Good Manufacturing Practice (CGMP) standards regulate the processes and quality controls used in pharmaceutical manufacturing. The FDA identified deviations from these standards during an inspection.
72,376 bottles were distributed across the United States, including Puerto Rico and Canada. The affected batches include R2100283, R2100288, R2100289, R2200235, R2201037, R2200952, and others, with expiration dates ranging from February 2023 to June 2024.
The recalled product
- Product
- ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)
- Brand
- ATORVASTATIN CALCIUM
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 72,376
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a)R2100283
- R2100288
- R2100289
- Exp. Date 2/28/2023
- R2200235
- Exp. Date 1/31/2024
- R2201037
- R2200952
- Exp. Date 6/30/2024
- b) R2100291
- R2100281
- R2100282
- R2100292
- R2100293
- R2100294
- R2100290
- R2100306
- R2100348
- R2100349
- R2100347
UPCs (2)
- 316729047159
- 316729047166
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · ATORVASTATIN CALCIUM
- ModerateAtorvastatin 10 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 20 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 40 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 80 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- HighBiocon Pharma atorvastatin calcium tablets recalled for failed dissolution specifications
FDA (Drugs) · 2025-04-09
Same manufacturer · Accord Healthcare, Inc.
See all →- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19